C

Celcuity Inc
NASDAQ:CELC

Watchlist Manager
Celcuity Inc
NASDAQ:CELC
Watchlist
Price: 112.12 USD -2.1% Market Closed
Market Cap: $5.2B

Celcuity Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Celcuity Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
C
Celcuity Inc
NASDAQ:CELC
Research & Development
-$140.8m
CAGR 3-Years
-67%
CAGR 5-Years
-82%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Research & Development
-$8.8B
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.8B
CAGR 3-Years
-2%
CAGR 5-Years
-1%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$6.8B
CAGR 3-Years
-15%
CAGR 5-Years
-10%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.9B
CAGR 3-Years
-16%
CAGR 5-Years
-16%
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$5.2B
CAGR 3-Years
-16%
CAGR 5-Years
-15%
CAGR 10-Years
-13%
No Stocks Found

Celcuity Inc
Glance View

Market Cap
5.2B USD
Industry
Biotechnology

Celcuity, Inc. is cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 39 full-time employees. The company went IPO on 2017-09-20. The firm is focused on discovering cancer sub-types molecular-based approaches through developing companion diagnostic tests (CDx) and therapeutic (Rx). The firm's product pipeline includes CELsignia platform and Gedatolisib. The CELsignia diagnostic platform is used to analyze live patient tumor cells to identify the specific abnormal cellular process driving a patients cancer and the targeted therapy. The CELsignia platform provides traditional molecular diagnostics, which includes snapshot of the genetic mutations present in a patients tumor because they analyze cell fragments and molecular diagnostics can estimate the patients potential drug response based on a statistical analysis of the drugs clinical trial result. Its other product candidate includes Gedatolisib, is a small molecule dual inhibitor, administered intravenously, that targets all Class I isoforms of PI3K and mammalian target of rapamycin (mTOR).

CELC Intrinsic Value
79.52 USD
Overvaluation 29%
Intrinsic Value
Price
C

See Also

What is Celcuity Inc's Research & Development?
Research & Development
-140.8m USD

Based on the financial report for Sep 30, 2025, Celcuity Inc's Research & Development amounts to -140.8m USD.

What is Celcuity Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-82%

Over the last year, the Research & Development growth was -59%. The average annual Research & Development growth rates for Celcuity Inc have been -67% over the past three years , -82% over the past five years .

Back to Top